Search research articles
Contact Us
Filters
Showing results (1251-1260 of 1,433) with videos related to
Page
of 144
Sort By:
Frontiers in Oncology
|
February 21, 2022
Corrigendum: Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors
Greta Caprara, Maria Tieri, Alessandra Fabi, et al.
American Journal of Hematology
|
September 29, 2011
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study
Sergio Siragusa, Alessandra Malato, Giorgia Saccullo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study
Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.
Frontiers in Oncology
|
November 22, 2021
Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors
Greta Caprara, Maria Tieri, Alessandra Fabi, et al.
The Journal of Dermatological Treatment
|
April 7, 2023
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy
Stefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Frontiers in Neurology
|
December 11, 2023
Electrophysiological neuromuscular alterations and severe fatigue predict long-term muscle weakness in survivors of COVID-19 acute respiratory distress syndrome
Marco Benedini, Marta Cogliati, Tea Lulic-Kuryllo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
PierFranco Conte, Giancarlo Bisagni, Federico Piacentini, et al.
Jac-Antimicrobial Resistance
|
December 15, 2021
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant <i>Pseudomonas aeruginosa</i> (DTR-P) infections
Marianna Meschiari, Sara Volpi, Matteo Faltoni, et al.
Scientific Reports
|
October 22, 2025
Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial
Francesco Di Pierro, Emanuela Giorgia Sampugnaro, Giovanna Erika Lomeo, et al.
Breast (Edinburgh, Scotland)
|
March 17, 2024
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
Federica Miglietta, Letizia Pontolillo, Carmine De Angelis, et al.
Page
of 144
Search research articles
Search
Showing results (1251-1260 of 1,433) with videos related to
Sort By:
Page
of 144
Frontiers in Oncology
|
February 21, 2022
Corrigendum: Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors
Greta Caprara, Maria Tieri, Alessandra Fabi, et al.
American Journal of Hematology
|
September 29, 2011
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study
Sergio Siragusa, Alessandra Malato, Giorgia Saccullo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study
Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.
Frontiers in Oncology
|
November 22, 2021
Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors
Greta Caprara, Maria Tieri, Alessandra Fabi, et al.
The Journal of Dermatological Treatment
|
April 7, 2023
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy
Stefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Frontiers in Neurology
|
December 11, 2023
Electrophysiological neuromuscular alterations and severe fatigue predict long-term muscle weakness in survivors of COVID-19 acute respiratory distress syndrome
Marco Benedini, Marta Cogliati, Tea Lulic-Kuryllo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
PierFranco Conte, Giancarlo Bisagni, Federico Piacentini, et al.
Jac-Antimicrobial Resistance
|
December 15, 2021
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant <i>Pseudomonas aeruginosa</i> (DTR-P) infections
Marianna Meschiari, Sara Volpi, Matteo Faltoni, et al.
Scientific Reports
|
October 22, 2025
Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial
Francesco Di Pierro, Emanuela Giorgia Sampugnaro, Giovanna Erika Lomeo, et al.
Breast (Edinburgh, Scotland)
|
March 17, 2024
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
Federica Miglietta, Letizia Pontolillo, Carmine De Angelis, et al.
Page
of 144